BlackRock Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9.76M	Sell	603,431 -2,302	-0.4%	-$41.7K	0.01%	1127
2016 Q3	$11M	Buy	605,733 +4,953	+0.8%	+$96.8K	0.01%	944
2016 Q2	$9.89M	Buy	600,780 +599,382	+42,874%	+$9.7M	0.01%	969
2016 Q1	$23K	Hold	1,398	–	–	﹤0.01%	3359
2015 Q4	$30K	Hold	1,398	–	–	﹤0.01%	3350
2015 Q3	$28K	Sell	1,398 -45,078	-97%	-$1.42M	﹤0.01%	3367
2015 Q2	$1.61M	Buy	+46,476	New	+$1.42M	﹤0.01%	2406
2014 Q3	–	Sell	-177,917	Closed	-$2.81M	–	4105
2014 Q2	$2.81M	Buy	177,917 +7,586	+4%	+$108K	﹤0.01%	1809
2014 Q1	$2.58M	Buy	170,331 +12,090	+8%	+$137K	﹤0.01%	1867
2013 Q4	$1.21M	Sell	158,241 -3,144	-2%	-$17K	﹤0.01%	2367
2013 Q3	$541K	Buy	161,385 +8,709	+6%	+$23K	﹤0.01%	2875
2013 Q2	$376K	Buy	+152,676	New	+$366K	﹤0.01%	3001

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Investment Management's HZNP Position: Q4 2016 in Review

BlackRock Investment Management reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 0.38% in Q4 2016, selling an estimated $41.7K and leaving 603,431 shares worth $9.76M. The position accounts for 0.01% of the portfolio, ranked #1127.

BlackRock Investment Management first reported a position in HZNP in Q2 2013 and has held it in 12 quarters since. The position peaked at $11M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

BlackRock Investment Management held 603,431 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $9.76M as of Q4 2016.
BlackRock Investment Management sold 2,302 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $41.7K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1127 holding.
BlackRock Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 12 quarters since.
BlackRock Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11M in Q3 2016.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.